GlaxoSmithKline Pakistan Limited reported a strong performance for the quarter ended March 31, 2026
Filed as: Financial Results for the Quarter Ended March 31, 2026
Summary
GlaxoSmithKline Pakistan Limited reported a strong performance for the quarter ended March 31, 2026, with revenue reaching Rs 17.03 billion and net profit increasing to Rs 2.61 billion.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 17.03 billion | PKR 15.58 billion | +9.3% |
| Net Profit | PKR 2.61 billion | PKR 2.13 billion | +22.8% |
| Gross Profit | PKR 6.38 billion | PKR 5.33 billion | +19.8% |
| Operating Profit | PKR 4.31 billion | PKR 3.63 billion | +18.6% |
| Earnings Per Share | PKR 8.20 | PKR 6.68 | +22.8% |
| Cash and Bank Balances | PKR 9.91 billion | PKR 8.59 billion | +15.2% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased by 9.29% to Rs 17.03 billion compared to Rs 15.58 billion in the same quarter last year.
- Net profit rose by 22.78% to Rs 2.61 billion from Rs 2.13 billion in the prior year period.
- Earnings per share improved to Rs 8.20 from Rs 6.68, indicating strong profitability growth.
GlaxoSmithKline Pakistan Limited (GLAXO) on Nafa
Last price Rs 336.89 · Pharmaceuticals · You can own GLAXO shares from your phone.
More GLAXO announcements
- NoticeTransmission of Quarterly Report for the Period Ended September 30, 2026
- Financial resultGlaxoSmithKline Pakistan Limited reported a revenue of Rs 48.11 billion for the nine months ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting Quarter 3-2026
- NoticeShariah Disclosure for the Half Year ended June 30, 2026
- NoticeCredit of Interim Cash Dividend
- NoticeAppointment of Chief Financial Officer
Source: GlaxoSmithKline Pakistan Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.